PDF(Pubmed)
Abstract：
Hematopoietic stem cell transplantation (HSCT) remains the only curative option for several hematological malignancies. Its use has continued to grow, with an estimated 23,500 transplants performed annually in the United States alone. The acute toxicities that occur from conditioning chemotherapy can impact the peri-transplant period and have substantial implications on patients\' tolerability and outcomes, irrespective of the treatment of their disease. Chemotherapy-induced nausea vomiting (CINV), mucositis, transplant-associated thrombotic microangiopathy (TA-TMA), and sinusoidal obstruction syndrome, also known as a veno-occlusive disease (SOS/VOD) can all have significant implications for patients. These acute complications begin with the start of conditioning chemotherapy and add to potential toxicity for patients throughout the early post-transplant period, from Day +30 for CINV, mucositis, and SOS, and which can continue through at least Day +100 with the onset of TA-TMA. These toxicities must be prevented and managed appropriately. This review will summarize the literature surrounding them and guide their management.
摘要：
造血干细胞移植（HSCT）仍然是几种血液恶性肿瘤的唯一治愈选择。它的使用持续增长，据估计，仅在美国，每年就有23,500例移植。预处理化疗引起的急性毒性可影响围移植期，并对患者的耐受性和预后产生重大影响。不管他们的疾病如何治疗。化疗引起的恶心呕吐（CINV），粘膜炎,移植相关血栓性微血管病（TA-TMA），和正弦阻塞综合征，也被称为静脉闭塞性疾病（SOS/VOD）都可能对患者产生重大影响。这些急性并发症始于预处理化疗的开始，并在整个移植后早期增加对患者的潜在毒性。从第30天开始，对于CINV，粘膜炎,和SOS,并且随着TA-TMA的开始可以持续至少第+100天。必须适当预防和管理这些毒性。这篇综述将总结围绕他们的文献并指导他们的管理。
